Highlights of the latest research for Tremfya (guselkumab) and investigational targeted oral peptide JNJ-2113 in moderate to severe plaque psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress,- Janssen Pharmaceuticals

Janssen will present new data on the underlying science of the treatment of psoriasis (PsO), including results from the Phase IIIb GUIDE trial highlighting early intervention with Tremfya (guselkumab) (Abstract #FC08.5) and systemic pharmacodynamica response data for JNJ-2113 from the Phase II FRONTIER 1 trial (Abstract #FC08.2).

In the GUIDE trial, the results experienced by super responders with short disease duration of PsO who were treated with Tremfya extended beyond high levels of Psoriasis Area and Severity Index (PASI) responses. These results support the potential for tailored therapeutic strategies, which could address individual patient needs, reinforcing the data on early intervention with Tremfya. In addition, new FRONTIER 1 data show for the first time that the targeted oral peptide JNJ 2113 induces a strong systemic pharmacodynamic response versus placebo in people living with moderate to severe plaque PsO. Investigational JNJ-2113 is the first and only targeted oral peptide designed to block the IL-23 receptor, which underpins the inflammatory response in PsO and other IL-23-mediated diseases.

“The breadth of data we are presenting at EADV underscores our commitment to developing new treatments for people living with moderate to severe plaque psoriasis, a disease that can cause significant physical and emotional burden,” said Lloyd Miller, M.D., Ph.D., Vice President, Immuno-dermatology Disease Area Stronghold Leader, Janssen Research & Development, LLC. “Patients are waiting for a new option with the goal of helping manage their plaque psoriasis symptoms, which could potentially transform the treatment paradigm. The data from these presentations add to the comprehensive body of scientific evidence for our investigational and established therapies, potentially offering people living with moderate to severe plaque psoriasis much-needed relief from their symptoms.”